Longitudinal Changes In Patient-Reported Symptoms And Physical Function During Taxane-Based Chemotherapy In Breast Cancer Patients.

10098Background: Chemotherapy-induced peripheral neuropathy (CIPN) is a dose-limiting toxicity of several commonly used chemotherapy drugs including taxanes, vinca alkaloids, and platinum compounds. Development of CIPN is highly variable, both in self-reported symptoms and functional consequences, and can be severe enough to alter dose intensity. The purpose of this pilot study was to gain insight into the natural history of both patient-reported and objective functional symptoms in breast cancer patients undergoing taxane-based chemotherapy. Methods: Thirty-two breast cancer patients (31 female/ 1 male; 47.6 ± 11.2 yr; n = 16 stage II/ n = 16 stage III) were enrolled. Patients completed self-reports of symptoms and function (e.g., EORTC QLQ-CIPN20) and objective measures of physical function (i.e., balance and gait testing) in an outpatient oncology clinic at five timepoints: (1) prior to starting chemotherapy to provide a baseline, (2-4) before starting subsequent chemotherapy cycles, and (5) 1-3 months...